Differentiation of lethal and non lethal prostate cancer: PSA and PSA isoforms and kinetics

Research output: Contribution to journalArticle

Abstract

Prostate-specific antigen (PSA) testing for the early diagnosis of prostate cancer has led to a decrease in cancer mortality. However, the high prevalence of low-grade prostate cancer and its long natural history, competing causes of death in older men and treatment patterns of prostate cancer, have led to dramatic overtreatment of the disease. Improved markers of prostate cancer lethality are needed to reduce the overtreatment of prostate cancer that leads to a reduced quality of life without extending life for a high proportion of men. The PSA level prior to treatment is routinely used in multivariable models to predict prostate cancer aggressiveness. PSA isoforms and PSA kinetics have been associated with more aggressive phenotypes, but are not routinely employed as part of prediction tools prior to treatment. PSA kinetics is a valuable marker of lethality post treatment and routinely used in determining the need for salvage therapy.

Original languageEnglish (US)
Pages (from-to)355-360
Number of pages6
JournalAsian Journal of Andrology
Volume14
Issue number3
DOIs
StatePublished - May 2012

Fingerprint

Prostate-Specific Antigen
Prostatic Neoplasms
Protein Isoforms
Salvage Therapy
Therapeutics
Natural History
Early Detection of Cancer
Cause of Death
Quality of Life
Phenotype
Mortality
Neoplasms
Medical Overuse

Keywords

  • benign PSA
  • human kallikrein 2
  • precursor form of PSA
  • prostate specific antigen
  • PSA kinetics
  • unbound or free PSA

ASJC Scopus subject areas

  • Urology

Cite this

Differentiation of lethal and non lethal prostate cancer : PSA and PSA isoforms and kinetics. / Carter, H Ballentine.

In: Asian Journal of Andrology, Vol. 14, No. 3, 05.2012, p. 355-360.

Research output: Contribution to journalArticle

@article{10521c24585e4acaa4676f996a5ed5a3,
title = "Differentiation of lethal and non lethal prostate cancer: PSA and PSA isoforms and kinetics",
abstract = "Prostate-specific antigen (PSA) testing for the early diagnosis of prostate cancer has led to a decrease in cancer mortality. However, the high prevalence of low-grade prostate cancer and its long natural history, competing causes of death in older men and treatment patterns of prostate cancer, have led to dramatic overtreatment of the disease. Improved markers of prostate cancer lethality are needed to reduce the overtreatment of prostate cancer that leads to a reduced quality of life without extending life for a high proportion of men. The PSA level prior to treatment is routinely used in multivariable models to predict prostate cancer aggressiveness. PSA isoforms and PSA kinetics have been associated with more aggressive phenotypes, but are not routinely employed as part of prediction tools prior to treatment. PSA kinetics is a valuable marker of lethality post treatment and routinely used in determining the need for salvage therapy.",
keywords = "benign PSA, human kallikrein 2, precursor form of PSA, prostate specific antigen, PSA kinetics, unbound or free PSA",
author = "Carter, {H Ballentine}",
year = "2012",
month = "5",
doi = "10.1038/aja.2011.141",
language = "English (US)",
volume = "14",
pages = "355--360",
journal = "Asian Journal of Andrology",
issn = "1008-682X",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Differentiation of lethal and non lethal prostate cancer

T2 - PSA and PSA isoforms and kinetics

AU - Carter, H Ballentine

PY - 2012/5

Y1 - 2012/5

N2 - Prostate-specific antigen (PSA) testing for the early diagnosis of prostate cancer has led to a decrease in cancer mortality. However, the high prevalence of low-grade prostate cancer and its long natural history, competing causes of death in older men and treatment patterns of prostate cancer, have led to dramatic overtreatment of the disease. Improved markers of prostate cancer lethality are needed to reduce the overtreatment of prostate cancer that leads to a reduced quality of life without extending life for a high proportion of men. The PSA level prior to treatment is routinely used in multivariable models to predict prostate cancer aggressiveness. PSA isoforms and PSA kinetics have been associated with more aggressive phenotypes, but are not routinely employed as part of prediction tools prior to treatment. PSA kinetics is a valuable marker of lethality post treatment and routinely used in determining the need for salvage therapy.

AB - Prostate-specific antigen (PSA) testing for the early diagnosis of prostate cancer has led to a decrease in cancer mortality. However, the high prevalence of low-grade prostate cancer and its long natural history, competing causes of death in older men and treatment patterns of prostate cancer, have led to dramatic overtreatment of the disease. Improved markers of prostate cancer lethality are needed to reduce the overtreatment of prostate cancer that leads to a reduced quality of life without extending life for a high proportion of men. The PSA level prior to treatment is routinely used in multivariable models to predict prostate cancer aggressiveness. PSA isoforms and PSA kinetics have been associated with more aggressive phenotypes, but are not routinely employed as part of prediction tools prior to treatment. PSA kinetics is a valuable marker of lethality post treatment and routinely used in determining the need for salvage therapy.

KW - benign PSA

KW - human kallikrein 2

KW - precursor form of PSA

KW - prostate specific antigen

KW - PSA kinetics

KW - unbound or free PSA

UR - http://www.scopus.com/inward/record.url?scp=84860856485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860856485&partnerID=8YFLogxK

U2 - 10.1038/aja.2011.141

DO - 10.1038/aja.2011.141

M3 - Article

C2 - 22343493

AN - SCOPUS:84860856485

VL - 14

SP - 355

EP - 360

JO - Asian Journal of Andrology

JF - Asian Journal of Andrology

SN - 1008-682X

IS - 3

ER -